A staging system capable of addressing the real issues facing patients with hepatocellular carcinoma has long been overdue. The new Hong Kong Liver Cancer staging system might do just that because it deals effectively with the limitations of previous staging systems.
This is a preview of subscription content, log in via an institution to check access.
Change history
08 May 2013
In the version of this article originally published online, the Node criterion for the BCLC staging system was incorrect in Table 1. The error has been corrected for the HTML and PDF versions of the article.
References
Forner, A., Llovet, J. M. & Bruix, J. Hepatocellular carcinoma. Lancet 379, 1245–1255 (2012).
European Association for the Study of the Liver & European Organisation for Research and Treatment of Cancer. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. J. Hepatol. 56, 908–943 (2012).
Llovet, J. M. et al. Sorafenib in advanced hepatocellular carcinoma. N. Engl. J. Med. 359, 378–390 (2008).
Burrel, M. et al. Survival of patients with hepatocellular carcinoma treated by transarterial chemoembolisation (TACE) using drug eluting beads. Implications for clinical practice and trial design. J. Hepatol. 56, 1330–1335 (2012).
Llovet, J. M., Schwartz, M., Fuster, J. & Bruix, J. Expanded criteria for hepatocellular carcinoma through down-staging prior to liver transplantation: not yet there. Semin. Liver Dis. 26, 248–253 (2006).
Llovet, J. M., Bru, C. & Bruix, J. Prognosis of hepatocellular carcinoma: the BCLC staging classification. Semin. Liver Dis. 19, 329–338 (1999).
Yau, T. et al. Development of Hong Kong liver cancer staging system with treatment stratification for patients with hepatocellular carcinoma. Gastroenterology, http://dx.doi.org/10.1053/j.gastro.2014.02.032 (2014).
Lencioni, R. et al. GIDEON (Global investigation of therapeutic decisions in hepatocellular carcinoma and of its treatment with sorafenib): second interim analysis. Int. J. Clin. Pract. http://dx.doi.org/10.1111/ijcp.12352 (2013).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
J.-F.G. acts as a consultant for the following companies: Bayer HealthCare, Biocompatibles/BTG, Guerbet, Jennerex, Nordion/BTG and Philips Healthcare. J.-F.G. is also the founder and CEO of PreScience Labs, LLC. J.C. declares no competing interests.
PowerPoint slides
Rights and permissions
About this article
Cite this article
Chapiro, J., Geschwind, JF. Have we finally found the ultimate staging system for HCC?. Nat Rev Gastroenterol Hepatol 11, 334–336 (2014). https://doi.org/10.1038/nrgastro.2014.67
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrgastro.2014.67
- Springer Nature Limited
This article is cited by
-
Prognostication and risk factor stratification for survival of patients with hepatocellular carcinoma: a nationwide big data analysis
Scientific Reports (2023)
-
Comparing HCC arterial tumour vascularisation on baseline imaging and after lipiodol cTACE: how do estimations of enhancing tumour volumes differ on contrast-enhanced MR and CT?
European Radiology (2020)
-
A New Prognostic Model Based on Albumin–Bilirubin Grade for Hepatocellular Carcinoma Beyond the Milan Criteria
Digestive Diseases and Sciences (2020)
-
Identification of a molecular subtyping system associated with the prognosis of Asian hepatocellular carcinoma patients receiving liver resection
Scientific Reports (2019)
-
Multicentric Assessment of the Hong Kong Liver Cancer Staging System in Chinese Patients Following Transarterial Chemoembolization
CardioVascular and Interventional Radiology (2018)